

Correction

Correction: Raab et al. Truncated DAPK Variants Restore Tumor Suppressor Activity and Synergize with Standard Therapies in High-Grade Serous Ovarian Cancer. *Cancers* 2025, 17, 1910

Monika Raab ¹, Khayal Gasimli ¹, Balázs Györffy ^{2,3,4}, Samuel Peña-Llopis ^{5,6}, Sven Becker ¹, Mourad Sanhaji ^{1,*,†} and Klaus Strebhardt ^{1,7,†}

- ¹ Department of Gynecology, Medical School, Goethe-University, 60596 Frankfurt am Main, Germany; mraab@med.uni-frankfurt.de (M.R.); khayal.gasimli@unimedizin-ffm.de (K.G.); sven.becker@ukffm.de (S.B.)
- ² Department of Bioinformatics, Semmelweis University, 1094 Budapest, Hungary; gyorffy.balazs@yahoo.com
- ³ Department of Biophysics, Medical School, University of Pecs, 7624 Pecs, Hungary
- ⁴ HUN-REN TTK Cancer Biomarker Research Group, 1117 Budapest, Hungary
- ⁵ Translational Genomics, Department of Ophthalmology, University Hospital Essen, 45147 Essen, Germany; samuel.pena-llopis@uk-essen.de
- ⁶ German Cancer Consortium (DKTK) at the University Hospital Essen and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
- ⁷ German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
- * Correspondence: mourad.sanhaji@ukffm.de
- † These authors contributed equally to this work.

In the original publication [1], an error occurred during the assembly of Figure 2E. The revised Figure 2E is now based on the correct assembly of the corresponding experimental data, and the original Western blot scans have been provided for transparency. The corrected Figure 2E is shown below.




Figure 2. (E) Ovarian cancer cell lines were treated with 10 μM of 5-Azacytidine for 24 h. Cell lysates were immunoblotted for DAPK1, PARP, and β-Actin.

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated as well as the Supplementary Materials.



Received: 26 June 2026

Accepted: 3 July 2026

Published: 21 July 2026

Copyright: © 2026 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the [Creative Commons Attribution \(CC BY\)](https://creativecommons.org/licenses/by/4.0/) license.

Reference

1. Raab, M.; Gasimli, K.; Györfy, B.; Peña-Llopis, S.; Becker, S.; Sanhaji, M.; Strebhardt, K. Truncated DAPK Variants Restore Tumor Suppressor Activity and Synergize with Standard Therapies in High-Grade Serous Ovarian Cancer. *Cancers* **2025**, *17*, 1910. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.